Dr. Socinski on Milestone of Immunotherapy in Lung Cancer – OncLive
OncLive |
Dr. Socinski on Milestone of Immunotherapy in Lung Cancer
OncLive 2015 was a monumental year because the community saw the approval of 2 immunotherapy drugs, nivolumab (Opdivo) and pembrolizumab (Keytruda)that replaced the former standard of care, which was docetaxel, in the second-line setting of advanced … |
